The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -12,888 | -29,447 |
| Stock-based compensation | 3,976 | 3,035 |
| Non-cash operating lease expense | 56 | 88 |
| Accretion of discounts on marketable securities, net | 523 | 1,240 |
| Depreciation and amortization expense | 29 | 38 |
| In-process research and development, related party | 0 | 0 |
| Unrealized foreign currency transaction (gain) loss | 1 | -24 |
| Prepaid expenses and other current assets | 1,382 | -1,272 |
| Other long-term assets | 162 | 1,352 |
| Accounts payable | -393 | 165 |
| Accounts payable and accrued liabilities, related party-Related Party | 0 | 0 |
| Accrued expenses and other current liabilities | -792 | 944 |
| Operating lease liabilities | -59 | -109 |
| Long-term liabilities | 0 | 0 |
| Net cash used in operating activities | -12,139 | -26,582 |
| Purchases of property and equipment | 109 | 77 |
| Purchases of marketable securities | 23,712 | 79,370 |
| Maturities of marketable securities | 39,081 | 41,482 |
| Issuance of promissory loan in connection with asset acquisition | 0 | 0 |
| Cash paid in connection with asset acquisition, net of cash received | 0 | 0 |
| Net cash used in investing activities | 15,260 | -37,965 |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from issuance of common stock in private placement, net of issuance costs | 0 | 0 |
| Net cash provided by financing activities | 0 | 0 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 0 |
| Net change in cash and cash equivalents | 3,121 | -64,547 |
| Cash and cash equivalents at beginning of period | 87,229 | - |
| Cash and cash equivalents at end of period | 25,803 | - |
Climb Bio, Inc. (CLYM)
Climb Bio, Inc. (CLYM)